Evenity (romosozumab) generally produces larger and faster gains in bone density than Prolia (denosumab), but calling one universally “better” oversimplifies a choice that depends on fracture risk, heart health, treatment history, and how long you plan to stay on therapy. The two drugs work through fundamentally different mechanisms, and in many cases the strongest approach uses both of them in sequence rather than picking one over the other.
How the Two Drugs Work
Prolia and Evenity are both injectable medications for osteoporosis, but they affect bone in almost opposite ways. Prolia (denosumab) is an anti-resorptive drug. It blocks a signaling molecule called RANKL that osteoclasts, the cells responsible for breaking down bone, need to form, function, and survive.1PubMed. The RANKL pathway and denosumab By neutralizing RANKL, Prolia slows bone breakdown, letting your existing bone-building cells gradually tip the balance toward denser bone over time.
Evenity (romosozumab) does something more unusual. It blocks a protein called sclerostin, which normally acts as a brake on bone formation. With that brake released, Evenity both ramps up new bone formation and dials down bone resorption at the same time.2Bone. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody This dual action is what makes it the first drug in its class and explains why bone density can climb so quickly during treatment.
The practical difference: Prolia protects what you have by slowing loss. Evenity actively builds new bone while also slowing loss. That distinction shapes everything from how fast each drug works to what happens when you stop taking it.
Bone Density Gains
In head-to-head comparisons, Evenity consistently outperforms Prolia on bone mineral density at the lumbar spine, the site most responsive to both drugs. A randomized trial in elderly women with osteoporosis found that lumbar spine density increased by about 14% with romosozumab versus roughly 9% with denosumab after 12 months, a statistically significant difference. The gap was already apparent at six months.3PubMed Central. A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis At the hip, though, the differences between the two were not significant in that same trial, which is worth keeping in mind if hip fracture is your main concern.
A separate study looking directly at denosumab versus romosozumab in postmenopausal women confirmed this pattern. Bone formation markers told a revealing story: Prolia suppressed a key formation marker (P1NP) by more than 60% at six months, meaning it was slowing down not just bone breakdown but also bone building. Evenity, by contrast, kept that same formation marker slightly elevated at six months before it gradually returned to baseline.4PubMed Central. Denosumab versus romosozumab for postmenopausal osteoporosis treatment This confirms that the density gains from Evenity come partly from genuine new bone formation, not just from slowing the removal of old bone.
A meta-analysis pooling data from multiple studies found that romosozumab’s bone-building signal is strongest early in treatment. Over time, the formation boost fades and the drug’s effect shifts toward an anti-resorptive profile more like Prolia’s.5PubMed Central. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis This is one reason Evenity is approved only for a 12-month course: the bone-building window closes, and extending treatment yields diminishing returns.
Beyond Density: Bone Quality
Bone density numbers, measured by a DEXA scan, capture how much mineral is packed into bone but say nothing about the internal structure. A measure called trabecular bone score (TBS) estimates that microarchitecture from the same DEXA image. Higher TBS indicates a more connected, resilient internal scaffolding that resists fracture better than a dense but structurally degraded bone would.
When researchers compared the two drugs on this measure, romosozumab improved TBS in postmenopausal women while denosumab showed almost no change.6PubMed Central. Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis This suggests that Evenity’s bone-building activity improves internal bone architecture in a way that simply stopping bone breakdown does not. It is one more piece of evidence that the density gains from Evenity are qualitatively different from those achieved with Prolia.
Fracture Prevention
Density and bone quality are surrogate measures. What patients actually care about is whether they break fewer bones. Both drugs reduce fractures compared to placebo, and a systematic evaluation of osteoporosis treatments found beneficial effects for both romosozumab and denosumab across vertebral, non-vertebral, and hip fractures, with hazard ratios ranging from 0.23 to 0.94 depending on the drug and fracture type.7PubMed Central. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
Evenity’s Phase III trials showed a roughly 73% reduction in vertebral fractures after one year compared to placebo. When patients took romosozumab for a year followed by denosumab in the second year, vertebral fracture risk dropped by about 75% compared to patients who received placebo the first year and denosumab the second.8PubMed Central. Profile of romosozumab and its potential in the management of osteoporosis Significant reductions in hip fractures were also seen in Phase III data.9PubMed Central. Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis
There is no large trial that directly randomized patients to romosozumab alone versus denosumab alone for years and then compared fracture counts. The fracture data we have for each drug comes mostly from trials against placebo or against other comparators like alendronate. So while Evenity’s faster density gains and structural improvements strongly suggest a fracture advantage, especially early on, the definitive head-to-head fracture comparison has not been run.
The Cardiovascular Question
This is where the comparison tilts in Prolia’s favor. Evenity carries a boxed warning about potential cardiovascular risk. An analysis of FDA adverse event reports found elevated reporting rates for major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) with romosozumab, with the composite signal driven heavily by reports from Japan.10PubMed Central. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) That analysis is based on spontaneous reports, not a controlled trial, which means it can flag a potential signal but cannot prove causation. Still, the FDA took the signal seriously enough to label Evenity with a warning against use in patients who have had a heart attack or stroke within the prior year.
Prolia does not carry a comparable cardiovascular warning. For someone with existing heart disease or significant cardiovascular risk factors, this distinction can make Prolia the safer choice regardless of Evenity’s density advantages. Your doctor will weigh your fracture risk against your cardiovascular risk before recommending one over the other, and for some patients that calculus points firmly toward Prolia.
What Happens When You Stop
Here the comparison flips dramatically. Stopping Prolia triggers one of the more alarming rebound effects in osteoporosis medicine. Within months of a missed or discontinued dose, bone breakdown surges. Patients can lose all the density they gained, and in some cases a burst of vertebral fractures occurs, sometimes multiple fractures at once.11PubMed Central. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature Most patients who stop Prolia experience rapid, profound bone loss, and a subset go on to develop these rebound-associated vertebral fractures.12PubMed Central. Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
This means that once you start Prolia, you essentially commit to either staying on it indefinitely or carefully transitioning to another anti-resorptive drug (usually a bisphosphonate like alendronate or zoledronic acid) to protect against the rebound. Missing even a single six-month dose can be enough to trigger the problem. Some patients with rebound-associated fractures after stopping denosumab have been treated with other osteoporosis medications to try to recover lost bone, but the evidence on how well that works is still developing.13Journal of Clinical Densitometry. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation
Evenity does not carry this same rebound risk because it is used for only 12 months, and patients are expected to transition to a maintenance drug afterward. The bone-building gains from Evenity appear to be more durable during the transition period, particularly when followed by an anti-resorptive. Prolia’s rebound problem does not mean it is a bad drug, but it does mean you need to plan your exit strategy before you start.
Why Doctors Often Use Both in Sequence
The emerging consensus for patients at very high fracture risk is not “Evenity or Prolia” but “Evenity first, then Prolia (or a bisphosphonate) afterward.” This approach front-loads Evenity’s bone-building phase, banking as much new bone and structural improvement as possible during the 12-month treatment window. Then a maintenance anti-resorptive like Prolia locks in those gains and prevents resorption from clawing them back.
The Phase III data bear this out: patients who took romosozumab for a year and then switched to denosumab maintained or continued to improve their density better than those who started on denosumab alone.8PubMed Central. Profile of romosozumab and its potential in the management of osteoporosis A case series examining a novel sequencing approach where patients already on denosumab were transitioned to romosozumab and then back to denosumab found that the anabolic effect of romosozumab still occurred even with overlapping denosumab exposure. Patients in that series saw lumbar spine gains of 5 to 22%, and no new vertebral fractures developed during the treatment window.14PubMed Central. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis
Sequencing also addresses the Prolia discontinuation problem. If you build bone aggressively with Evenity and then maintain it with Prolia, you can eventually plan a supervised transition from Prolia to a bisphosphonate when the time comes, having started from a higher bone density baseline.
Does Prior Treatment Blunt Evenity’s Effect?
One important caveat: if you have already been on an anti-resorptive for years before starting Evenity, you will not get the same density boost as someone starting treatment for the first time. A study examining this effect found that lumbar spine BMD gains from romosozumab were about 13% in treatment-naïve patients, roughly 9% in those with prior bisphosphonate use, and only about 4% in those who had previously been on denosumab.15Bone. The effect of prior osteoporosis treatment on bone mineral density response to romosozumab
This is clinically meaningful. It suggests that the ideal scenario is to use Evenity early, before cycling through other drugs, and it raises questions about switching from Prolia to Evenity mid-course. The bone-building response is still present in previously treated patients, but it is significantly attenuated. If your doctor is considering Evenity for you and you have been on Prolia for several years, they should factor in this blunted response when setting expectations.
Men with Osteoporosis
Most osteoporosis research focuses on postmenopausal women, but both drugs are used in men. A retrospective study comparing the two in male patients found that romosozumab produced significantly greater lumbar spine BMD increases than denosumab, consistent with the pattern seen in women.16Scientific Reports. Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study The researchers noted that Evenity’s bone-forming mechanism may be particularly well-suited to male osteoporosis, which tends to involve reduced bone formation more than accelerated bone loss. The evidence base for men is much thinner than for women, but the direction of the findings is consistent.
Kidney Function and Hypocalcemia
Both drugs can cause low blood calcium (hypocalcemia), but the risk with Prolia is higher in people with impaired kidney function. A case report highlighted severe hypocalcemia following denosumab in a patient with chronic kidney disease, and the broader literature supports that altered kidney function increases this risk.17PubMed Central. Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report Adequate calcium and vitamin D supplementation before starting either drug is standard practice, but monitoring is especially important with Prolia in patients whose kidneys do not handle calcium efficiently.
On the other hand, Prolia has an advantage for some patients with kidney problems: because it is cleared by the immune system rather than filtered through the kidneys, its dosing does not need adjustment for renal impairment in the way some bisphosphonates do. Evenity is similarly cleared without renal dose adjustment. The kidney concern is less about which drug to choose and more about how closely calcium levels need monitoring once treatment starts.
Rare but Serious Complications with Long-Term Use
Both Prolia and Evenity belong to the broader category of bone-modifying therapies that carry rare risks of atypical femoral fractures and osteonecrosis of the jaw. These complications are associated primarily with long-term anti-resorptive use. Because Evenity is used for only 12 months, the practical risk of these events during the romosozumab phase is very low. With Prolia, which many patients take for years, the risk accumulates over time, though it remains rare in absolute terms.18PubMed Central. Atypical femoral fracture and jaw osteonecrosis under high doses of denosumab, healed with the aid of low dose of denosumab: a case report
These complications create a therapeutic Catch-22 for long-term Prolia users: if an atypical femoral fracture or jaw osteonecrosis develops, the instinct is to stop the drug, but discontinuation triggers the rebound bone-loss phenomenon. Clinicians have had to get creative, sometimes using lower doses of denosumab to allow healing while preventing the rebound surge. The rarity of these events means most patients will never face this dilemma, but it underscores why long-term treatment planning matters.
Cost and Access
Both drugs are expensive branded biologics, and cost can be a deciding factor for many patients. Evenity requires monthly injections for 12 months (two shots per visit, given in a clinic), while Prolia is one injection every six months, typically for an indefinite period. Insurance coverage varies widely, and prior authorization requirements often apply, especially for Evenity. Some insurers require evidence that cheaper options like bisphosphonates have failed or are inappropriate before approving either drug. For patients paying out of pocket, the total cost of a 12-month Evenity course is comparable to about two years of Prolia, but the comparison gets complicated by the fact that Prolia use typically extends well beyond two years.
Practical Considerations for Choosing
The decision between these two drugs, or the decision to use them in sequence, depends on several interacting factors:
- Fracture risk: Patients at imminent high risk (recent fractures, very low bone density, high fall risk) are the strongest candidates for Evenity first, because it builds bone the fastest.
- Heart health: A history of heart attack or stroke within the past year makes Evenity a poor fit. Significant cardiovascular risk factors also weigh the decision toward Prolia or a bisphosphonate.
- Treatment history: Starting treatment for the first time? Evenity’s benefit is at its peak. Already several years into Prolia or a bisphosphonate? The expected gain from switching to Evenity will be smaller.
- Commitment to long-term therapy: If you are unlikely to stay on treatment consistently, Prolia’s rebound risk makes it more dangerous to start and then abandon. A 12-month Evenity course followed by a bisphosphonate may be a more forgiving path.
- Kidney function: Both drugs can be used regardless of kidney function, but calcium monitoring with Prolia is especially important if your kidneys are impaired.
Neither drug is categorically better. Evenity wins on speed, density gains, bone quality, and the simplicity of a defined 12-month course. Prolia wins on cardiovascular safety profile, long track record, ease of dosing (twice a year rather than monthly), and broad insurance access. The strongest evidence-based strategy for severe osteoporosis uses Evenity to build bone first and Prolia or a bisphosphonate to keep it, making the two drugs complementary rather than competing.